一项针对无脉络膜症患者的前瞻性、观察性、非干预性临床研究:NIGHT研究
NIGHT研究是一项前瞻性、观察性、多中心队列研究,纳入220例基因确诊的无脉络膜症男性患者,随访20个月,评估自然病史并确定最敏感进展指标。结果显示最佳矫正视力(BCVA)在20个月内稳定,而视网膜敏感度、中心椭圆体带面积和眼底自发荧光总面积在12个月时较基线下降,比BCVA更敏感。未发生与评估相关的严重不良事件。
要点
- BCVA在20个月内平均保持稳定,多数患者变化在-5个ETDRS字母以内。
- 视网膜敏感度、中心椭圆体带面积和眼底自发荧光总面积在12个月时较基线下降。
- 上述功能和解剖学指标比BCVA更敏感地反映无脉络膜症自然进展。
核心结论
- 视网膜敏感度、中心椭圆体带面积和眼底自发荧光总面积在测量无脉络膜症自然进展方面比BCVA更敏感。
研究设计与样本
- 前瞻性、观察性、多中心队列研究,纳入年龄≥18岁、基因确诊无脉络膜症、黄斑区可见活动性疾病且基线BCVA≥34个ETDRS字母的男性患者,随访20个月。
主要发现
- 共220例参与者完成研究,BCVA在20个月内平均保持稳定。
- 第20个月时,较差眼81.4%、较好眼77.8%的参与者BCVA较基线变化>-5个ETDRS字母。
- 眼间对称性总体较低。
- 从基线到第12个月,视网膜敏感度下降(较差眼-0.68 dB,较好眼-0.48 dB),中心椭圆体带面积减少(较差眼-0.276 mm2,较好眼-0.290 mm2),眼底自发荧光总面积减少(较差眼-0.605 mm2,较好眼-0.533 mm2)。
- 未发生与评估相关的严重不良事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The NIGHT study aimed to assess the natural history of choroideremia (CHM), an X-linked inherited chorioretinal degenerative disease leading to blindness, and determine which outcomes would be the most sensitive for monitoring disease progression. DESIGN: A prospective, observational, multicenter cohort study. METHODS: Males aged ≥18 years with genetically confirmed CHM, visible active disease within the macular region, and best-corrected visual acuity (BCVA) ≥34 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline were assessed for 20 months. The primary outcome was the change in BCVA over time at Months 4, 8, 12, 16, and 20. A range of functional and anatomical secondary outcome measures were assessed up to Month 12, including retinal sensitivity, central ellipsoid zone (EZ) area, and total area of fundus autofluorescence (FAF). Additional ocular assessments for safety were performed. RESULTS: A total of 220 participants completed the study. The mean BCVA was stable over 20 months. Most participants (81.4% in the worse eye and 77.8% in the better eye) had change from baseline > -5 ETDRS letters at Month 20. Interocular symmetry was low overall. Reductions from baseline to Month 12 were observed (worse eye, better eye) for retinal sensitivity (functional outcome; -0.68 dB, -0.48 dB), central EZ area (anatomical outcome; -0.276 mm2, -0.290 mm2), and total area of FAF (anatomical outcome; -0.605 mm2, -0.533 mm2). No assessment-related serious adverse events occurred. CONCLUSIONS: Retinal sensitivity, central EZ area, and total area of FAF are more sensitive than BCVA in measuring the natural progression of CHM.
引用
- Maclaren RE, Lam BL, Fischer MD, et al. A Prospective, Observational, Non-interventional Clinical Study of Participants With Choroideremia: The NIGHT Study. Am J Ophthalmol. 2024. PMID: 38311152. doi:10.1016/j.ajo.2024.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。